JP2020533302A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533302A5
JP2020533302A5 JP2020513684A JP2020513684A JP2020533302A5 JP 2020533302 A5 JP2020533302 A5 JP 2020533302A5 JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020533302 A5 JP2020533302 A5 JP 2020533302A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
prophylactic
mic
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020513684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/074263 external-priority patent/WO2019048660A1/en
Publication of JP2020533302A publication Critical patent/JP2020533302A/ja
Publication of JP2020533302A5 publication Critical patent/JP2020533302A5/ja
Withdrawn legal-status Critical Current

Links

JP2020513684A 2017-09-10 2018-09-10 肥満の治療において使用するためのmic−1およびglp−1 Withdrawn JP2020533302A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190270.3 2017-09-10
EP17190270 2017-09-10
PCT/EP2018/074263 WO2019048660A1 (en) 2017-09-10 2018-09-10 MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY

Publications (2)

Publication Number Publication Date
JP2020533302A JP2020533302A (ja) 2020-11-19
JP2020533302A5 true JP2020533302A5 (https=) 2021-09-24

Family

ID=59901361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513684A Withdrawn JP2020533302A (ja) 2017-09-10 2018-09-10 肥満の治療において使用するためのmic−1およびglp−1

Country Status (6)

Country Link
US (1) US11260108B2 (https=)
EP (1) EP3681529A1 (https=)
JP (1) JP2020533302A (https=)
CN (1) CN111163795A (https=)
MA (1) MA50233A (https=)
WO (1) WO2019048660A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3934679A1 (en) * 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
US12544427B2 (en) 2019-10-04 2026-02-10 Amgen Inc. Use of GDF15 for treating cardiometabolic syndrome and other conditions
BR112022011540A2 (pt) * 2019-12-11 2022-09-06 Lg Chemical Ltd Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero
CN115260313B (zh) * 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2022089435A1 (en) 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1734986B1 (en) 2004-04-13 2015-11-11 St Vincent's Hospital Sydney Limited Method for modulating appetite
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN103533951B (zh) * 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子15(gdf−15)ポリペプチド
JP6254146B2 (ja) * 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
TWI648401B (zh) 2013-07-31 2019-01-21 安美基公司 生長分化因子15(gdf-15)構築體
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As Mic-1 fusion proteins and uses thereof
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2020533302A5 (https=)
CL2021000158A1 (es) Compuestos coagonistas de gip/glp1
JP2020033360A5 (https=)
JP2016106150A5 (https=)
JP2009525343A5 (https=)
JP2017506624A5 (https=)
DK1173178T3 (da) Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2020503269A5 (https=)
JP2019517542A5 (https=)
JP2017160178A5 (https=)
JP2008505857A5 (https=)
JP2020500864A5 (https=)
JP2018530578A5 (https=)
JP2020536121A5 (https=)
JP2017519762A5 (https=)
JP2011500589A5 (https=)
JP2018506533A5 (https=)
RU2013157398A (ru) Композиция
JP2019507786A5 (https=)
JP2009539916A5 (https=)
MXPA05012299A (es) Composicion farmaceutica que comprende valsartan.
JP2006517557A5 (https=)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
JP2011500650A5 (https=)